Results 161 to 170 of about 265,634 (254)

PGI2 signaling metabolically reprograms CD4 Th2 cells and represses allergic airway inflammation. [PDF]

open access: yesJ Immunol
Zhou W   +10 more
europepmc   +1 more source

Gata3 ZsG and Gata3 ZsG-fl: Novel murine Gata3 reporter alleles for identifying and studying Th2 cells and ILC2s in vivo. [PDF]

open access: yesFront Immunol, 2022
Gurram RK   +10 more
europepmc   +1 more source

A Comparison of Realized Measures of Integrated Volatility: Price Duration‐ vs. Return‐Based Approaches

open access: yesJournal of Forecasting, EarlyView.
ABSTRACT We study the accuracy of a variety of parametric price duration‐based realized variance estimators constructed via various financial duration models and compare their forecasting performance with the performance of various nonparametric return‐based realized variance estimators.
Björn Schulte‐Tillmann   +2 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Guideline for the In Vivo Immunomodulatory Activity Test of Polysaccharide Based on Cyclophosphamide‐Induced Mouse Model

open access: yesFood Safety and Health, EarlyView.
Abstract graph of the in vivo immunomodulatory activity of polysaccharide based on a cyclophosphamide‐induced mouse model. ABSTRACT The immune system serves as the primary defense mechanism against pathogens and plays a vital role in maintaining host homeostasis. In recent years, natural polysaccharides have emerged as promising immunomodulators due to
Wenlei Nie   +3 more
wiley   +1 more source

Metabolic adaptations of ILC2 and Th2 cells in type 2 immunity. [PDF]

open access: yesCurr Opin Immunol
Kania AK   +3 more
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy